Hepatitis C virus and organ transplantation

Transplantation

Volumn 62, Issue 2, 1996, Pages 147-154

  Fishman, Jay A ^a   Rubin, Robert H ^a,b   Koziel, Margaret J ^a   Periera, Brian J G ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS C VACCINE; IMMUNOGLOBULIN; LAMIVUDINE; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SUPERINFECTION; VIRUS NEUTRALIZATION;

HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION;

EID: 0029999393     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199607270-00001     Document Type: Review

References (100)

1. Houghton M, Weiner A, Han J, Kou G, Choo Q-L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991; 14: 381.
2. American Association of Tissue Banks. Standards for tissue banking. McLean, VA: American Association of Tissue Banks, 1993.
3. American Association of Tissue Banks. Technical manual for tissue banking. McLean, VA: Association of Tissue Banks, 1992.
4. Busch M, Wilber J, Johnson P, et al. Impact of specimen handling and storage on detection of hepatitis C virus RNA. Transfusion 1993; 33: 420.
5. Campagnare D, Omally J. Standards of the American Red Cross Tissue Services. Washington, D.C. American Red Cross Tissue Services, 1994.
6. Centers for Disease Control. Semen banking, organ and tissue transplantation, and HIV antibody testing. MMWR 1988; 37: 57.
7. Comeau AM, Harris J, McIntosh K, et al. Polymerase chain reaction in detecting HIV infection among seropositive infants: relation to clinical status and age and to results of other assays. J Acquir Immun Defic Syndr 1992; 5: 271.
8. Bouffard P, Hayashi PH, Acevedo R, Levy N, Zeldis JB. Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis 1992; 166; 1276.
9. Miller HM, Pfaff E, Goeser T, Kallinowski B, Solbach C, Theilmann L. Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication. J Gen Virol 1993; 74: 669.
10. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41.
11. Fong TL, Shindo M, Feinstone SM, Hoofnagle JH, Di Bisceglie AM. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest 1991; 88: 1058.
12. Lamas E, Baccarini P, Housset C, Kremsdorf D, Brechot C. Detection of hepatitis C virus (HCV) RNA sequences in liver tissue by in situ hybridization. J Hepatol 1992; 16: 219.
13. Qian C, Camps J, Maluenda MD, Civeira MP, Prieto J. Replication of hepatitis C virus in peripheral blood mononuclear cells: effect of alpha-interferon therapy. J Hepatol 1992; 16: 380.
14. Zignego AL, Macchia D, Monti M, et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 1992; 15: 382.
15. Simmonds P. Variability of Hepatitis C Virus. Hepatology 1995; 21: 570.
16. Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 1088.
17. Alter HJ. Descartes before the horse: I clone, therefore I am: The hepatitis C virus in current perspective. Ann Intern Med 1991; 115: 644.
18. Gretch DR, dela Rosa C, Carithers RL, Jr., Willson RA, Williams B, Corey. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med 1995; 123: 321.
19. Rubin R, Falestiny M, Malet P. Chronic hepatitis C: advances in diagnostic testing and therapy. Arch Intern Med 1994; 154: 387.
20. Purcell RH. Hepatitis C virus: historical perspective and current concepts. FEMS Microbiol Rev 1994; 14: 181.
21. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906.
22. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899.
23. Roth D, Fernandez JA, Burke GW, Esquenazi V, Miller J. Detection of antibody to hepatitis C virus in renal transplant recipients. Transplantation 1991; 51: 396.
24. Chien DY, Choo QL, Ralston R, et al. Persistence of HCV despite antibodies to both putative envelope glycoproteins. Lancet 1993; 342: 933.
25. Iwarson S, Norkrans G, Wejstal R. Hepatitis C: natural history of a unique infection. Clin Infect Dis 1995; 20: 1361.
26. Dusheiko GM. The pathogenesis, diagnosis, and management of viral hepatitis. Alim Pharmacol Therap 1994; 8: 229.
27. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 6547.
28. Sallie R, Di Bisceglie AM. Viral hepatitis and hepatocellular carcinoma. Gastroenterol Clin North Am 1994; 23: 567.
29. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994; 68: 1494.
30. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91: 7792.
31. Farci P, London WT, Wong DC, et al. The natural history of infection with hepatitis C virus (HCV) in chimpanzees: comparison of serologic responses measured with first- and second-generation assays and relationship to HCV viremia. J Infect Dis 1992; 165: 1006.
32. Prince A, Brotman B, Hiuma T, Pascual D, Jafferry M, Inchauspe G. Immunity in hepatitis C infection. J Infect Dis 1992; 165: 438.
33. Koziel M, Dudley D, Afdhal N, et al. Hepatitis C virus-specific cytotoxic T lymphocytes recogognize epitopes in the core and envelope proteins of HCV. J Virol 1993; 67: 7522.
34. Koziel MJ, Dudley D, Wong JT, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149: 3339.
35. Minutello MA, Pileri P, Unutmaz D, et al. Compartmentalization of T lymphocytes to the site of disease; intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993; 178: 17.
36. Weiner A, Erickson AL, Kansopon J, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995; 92: 2755.
37. Ware AJ, Luby JP, Hollinger B, et al. Etiology of liver disease in renal transplant patients. Ann Intern Med 1979; 91: 364.
38. Tesi RJ, Waller MK, Morgan CJ, et al. Use of low-risk HCV-positive donors for kidney transplantation. Transplant Proc 1993; 25: 1472.
39. Tesi RJ, Waller K, Morgan CJ, et al. Transmission of hepatitis C by kidney transplantation - the risks. Transplantation 1994; 57: 826.
40. Pereira BJG, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325: 454.
41. Pereira BJG, Milford EL, Kirkman RL, et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the reipicents of their organs. N Engl J Med 1992; 327: 910.
42. Pereira BJ, Wright TL, Schmid CH, Levey AS. A controlled study of hepatitis C transmission by organ transplantation. Lancet 1995; 345: 484.
43. Martin P, Friendman LS. Chronic viral hepatitis and the management of chronic renal failure. Kidney Int 1995; 47: 1231.
44. Pereira BJG, Wright TI, Schid CH, et al. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus: a US National Collaborative Study. Kidney Int 1994; 46: 886.
45. Alter MJ. Transmission of hepatitis C virus - route, dose and titer. N Engl J Med 1994; 330: 784.
46. Zucker K, Cirocco R, Roth D, et al. Depletion of hepatitis C virus from procured kidneys using pulsative perfusion preservation. Transplantation 1994; 57: 832.
47. Stempel CA, Lake J, Kuo G, Vincenti F. Hepatitis C - its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 1993; 55: 273.
48. Ynares C, Johnson HK, Kerlin T, Crowe D, MacDonell R, Richie R. Impact of pretransplant hepatitis C antibody status upon long-term patient and renal allograft survival - a 5- and 10-year follow-up. Transplant Proc 1993; 25: 1466.
49. Pereira BJG, Milford EL, Kirkman RL, et al. Liver disease and HCV infection after transplantation of organs from Hepatitis C antibody positive donors. Transplant Proc 1993; 25: 1458.
50. Roth D, Zucker K, Cirocco R, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45: 238.
51. Mahony J. Long term results and complications of transplantation: the kidney. Transplant Proc 1989; 21: 1433.
52. Chan TM, Wu PC, Lau JY, Lai CL, Lok AS, Cheng IK. Clinicopathologic features of hepatitis C virus infection in renal allograft recipients. Transplantation 1994; 58: 996.
53. Feray C, Gigou M, Samuel D, et al. The course of Hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 1137.
54. Periera BJG, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799.
55. LaQuaglia MP, Tolkoff-Rubin NE, Dienstag JL, et al. Impact of hepatitis on renal transplantation. Transplantation 1981; 32: 504.
56. Cadranel J, Grippon P, Lunel F, et al. Chronic liver dysfunction in heart transplant recipients, with special reference to viral B, C and non-A, non-B, non-C hepatitis. Transplantation 1991; 52: 645.
57. Poterucha J, Rakela J, Lumeng L, et al. Diagnosis of chronic hepatitis C after liver transplantation by the detection of viral sequences with polymerase chain reaction. Hepatology 1992; 15: 42.
58. Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994; 20: 24S.
59. Konig V, Bauditz J, Lobeck H, et al. Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. Hepatology 1992; 16: 1137.
60. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317.
61. Samuel D, Gigou M, Feray C, et al. Recombinant alpha interferon for hepatitis C on the graft in liver transplant patients. Hepatology 1992; 16: 48A.
62. Feray C, Samuel D, Thiers V, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89: 1361.
63. Schluger L, Min A, Wolf D, et al. Severe cholestatic hepatitis C following orthotopic liver transplantation. Gastroenterology 1994; 106: A978.
64. Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994.
65. Hu K, Yu C, Vierling JM. Direct detection of circulating hepatitis C virus RNA using probes from the 5′ untranslated region. J Clin Invest 1992; 89: 2040.
66. Read AE, Donegan E, Lake J, et al. Hepatitis C in orthotopic liver transplant recipients. Ann Intern Med 1991; 114: 282.
67. Martin P, Munoz SJ, Di Bisceglie AM, et al. Recurrence of hepatitis C virus infection after orthotopic liver transplantation. Hepatology 1991; 13: 719.
68. Franza A, Miguet JP, Bresson-Hadni S, et al. Prevalence of hepatitis C antibodies in orthotopic liver transplantation: a sequential study of 72 patients. Transplant Proc 1991; 23: 1506.
69. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13.
70. Qu D, Li J, Vitvitski L, et al. Hepatitis C virus genotypes in France: comparison of clinical features of patients infected with HCV type 1 and type 2. J Hepatol 1994; 21: 70.
71. Brechot C. Hepatitis C virus genetic variability: clinical implications. Am J Gastroenterol 1994; 89: 541.
72. Gane EJ, Tibbs CJ, Ramage JK, Portmann BC, Williams R. Ribavinin therapy for hepatitis C infection following liver transplantation. Transplant Int 1995; 8: 61.
73. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective antibody against reinfection with hepatitis C virus. Science 1992; 258: 135.
74. Widell A, Mansson S, Perrson NH, Thysell H, Hermodsson S, Blohme I. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 1995; 60: 642.
75. Morales JM, Campistol JM, Castellano G, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995; 47: 236.
76. Gretch D, Wile M, Gaur L, et al. Donor-recipient match at the HLA-DQ beta locus is associated with recrudescence of chronic hepatitis following liver transplantation for end-stage hepatitis C. Hepatology 1993; 18: 108A.
77. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30.
78. Mueller AR, Platz KP, Bechstein WO, et al. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. Transplant Proc 1994; 26: 3637.
79. Tanaka H, Hiyama T, Okubo Y, Kitada A, Fujimoto I. Primary liver cancer incidence-rates related to hepatitis-C virus infection: a correlation study in Osaka, Japan. Cancer Causes Control 1994; 5: 61.
80. Chang CC, Uy MW, Lu CF, Yang CS, Chen CJ. A nested case-control study on association between hepatitis C virus antibodies and primary liver cancer in a cohort of 9775 men in Taiwan. J Med Virol 1994; 43: 276.
81. Paterlini P, Driss F, Nalpas B, et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology 1993; 17: 20.
82. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus non-structural protein NS3 transforms NIH 3T3 cells. J Virology 1995; 69: 3893.
83. Takada N, Takase S, Takada A, Date T. Differences in the hepatitis C virus genotypes in different countries. J Hepatology 1993; 17: 277.
84. Feray C, Samuel D, Gigou M, Reynes M, Bismuth H. Reduced incidence of recurrent and acquired infection by HCV after liver transplantation in patients receiving immunoglobulins. Hepatology 1994; 20: 131A.
85. Saleh MG, Tibbs CJ, Koskinas J, et al. Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. Hepatology 1994; 20: 1399.
86. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989; 321: 1501.
87. Wright HI, Gavaler JS, Van Thiel DH. Preliminary experience with a-2b interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53: 121.
88. Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994; 330: 1160.
89. Wright TL, Combs C, Kim M, et al. Interferon-a therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773.
90. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77.
91. Villamil FG, Vierling JM. Recurrence of viral hepatitis after liver transplantation: insights into management. Liver Transplant Surg 1995; 1: 89.
92. Hirsch MS, Schooley RY, Cosimi AB, Russell PS, Delmonico FL, et al. Effects of interferon alpha on cytomegalovirus reactivation syndromes in renal transplant recipients. N Engl J Med 1983; 308: 1489.
93. Kramer P, Ten Kate FWJ, Bijnen AB, Jeekel J, Weimar W. Recombinant leukocyte interferon A induces steroid resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989.
94. Rezieg M, Altraif I, Roach C, et al. Treatment of hepatitis C viral infection (HCV) in the transplanted patient with ribavirin. Hepatology 1993; 18: A342.
95. Rensen PCN, Van Dijk MCM, Havenaar EC, Bijsterbosch MK, Kruijt JK, Van Berkel TJC. Selective liver targeting of antivirals by recombinant chylomicrons - a new therapeutic approach to hepatitis B. Nature (Med) 1995; 1: 221.
96. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294.
97. Lagging LM, Meyer K, Hoft D, Houghton M, Belshe RB, Ray R. Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 1995; 69: 5859.
98. Major ME, Vitvitski L, Mink MA, et al. DNA-based immuniza-tion with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol 1995; 69: 5798.
99. Centers for Disease Control. 21 CFR 1270, Human tissue intended for transplantation. Fed Register 1993; 58: 65, 514.
100. Kubo M, Fujimoto N, Ihara H, et al. Prevalence and clinical significance of hepatitis C in kidney transplantation. Transplant Proc 1994; 26: 2121.